Delving into the Latest Updates on Zhuhai Ebang Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Immune System Diseases

Respiratory Diseases

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

CYP51A1(Cytochrome P450 51)	1

主要目的： 1. 比较单次/多次静脉滴注受试制剂或参比制剂注射用伏立康唑后中国健康受试者的安全性和耐受性。 2. 考察受试制剂和参比制剂的主要药代动力学参数是否满足生物等效。次要目的：比较单次/多次静脉滴注受试制剂或参比制剂注射用伏立康唑后的药代动力学特征。

[Translation]

Primary objectives: 1. To compare the safety and tolerability of single/multiple intravenous infusions of the test formulation or the reference formulation of voriconazole for injection in Chinese healthy subjects. 2. To investigate whether the main pharmacokinetic parameters of the test formulation and the reference formulation meet the bioequivalence. Secondary objectives: To compare the pharmacokinetic characteristics of the test formulation or the reference formulation of voriconazole for injection after single/multiple intravenous infusions.

Start Date26 Aug 2022

Sponsor / Collaborator

Zhuhai Ebang Pharmaceutical Co. Ltd.

CTR20213005 / CompletedPhase 1

注射用伏立康唑在健康受试者中的耐受性评价和药代动力学比较研究

[Translation] Tolerability evaluation and pharmacokinetic comparison of voriconazole for injection in healthy subjects

1.比较单次/多次静脉滴注受试制剂和参比制剂注射用伏立康唑后中国健康受试者的安全性和耐受性。 2.比较单次/多次静脉滴注受试制剂和参比制剂注射用伏立康唑后的药代动力学特征。 3.考察受试制剂和原研制剂的主要药代动力学参数是否满足生物等效。

[Translation]

1. Compare the safety and tolerability of the test formulation and the reference formulation of voriconazole injection in Chinese healthy subjects after single/multiple intravenous infusion. 2. Compare the pharmacokinetic characteristics of the test formulation and the reference formulation of voriconazole injection after single/multiple intravenous infusion. 3. Investigate whether the main pharmacokinetic parameters of the test formulation and the original formulation meet the bioequivalence.

Start Date20 Nov 2021

Sponsor / Collaborator

Zhuhai Ebang Pharmaceutical Co. Ltd.

100 Clinical Results associated with Zhuhai Ebang Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Zhuhai Ebang Pharmaceutical Co. Ltd.

Login to view more data

2

Literatures (Medical) associated with Zhuhai Ebang Pharmaceutical Co. Ltd.

02 Jun 2016·XenobioticaQ4 · MEDICINE

Effect of grapefruit juice and food on the pharmacokinetics of pirfenidone in healthy Chinese volunteers: a diet–drug interaction study

Q4 · MEDICINE

Article

Author: Zhu, Xiuqing ; Xu, Xinwen ; Lu, Haoyang ; Qiu, Chang ; Zhang, Ming ; Deng, Shuhua ; Ni, Xiaojia ; Hu, Jinqing ; He, Xiuling ; Shang, Dewei ; Huang, Wencan ; Wang, Zhanzhang ; Wen, Yuguan

1. Ingestion of grapefruit juice and food could be factors affecting the pharmacokinetics of pirfenidone, a promising drug for treatment of idiopathic pulmonary fibrosis. 2. A randomized, open-label, three-period crossover study was carried out in 12 healthy Chinese male volunteers who were randomized to one of the three treatments: pirfenidone tablets (0.4 g) were orally administered to fasted or fed subjects, or with grapefruit juice. The washout period was 7 d. 3. Significantly reduced maximum plasma concentration (Cmax, 5.0 5 ± 1.39 versus 10.9 0 ± 2.94 mg·L(- 1)), modestly affected area-under-the-plasma concentration-time curve (AUC) from time zero to 12 h post dosing (AUC0-12 h, 21.8 9 ± 6.47 versus 26.1 6 ± 7.32 mg·h·L(- 1)) and delayed time to reach Cmax (Tmax) were observed in fed group compared with fasted group. Similar effects on Cmax (5.8 2 ± 1.23 versus 10.9 0 ± 2.94 mg·L(- 1)) and AUC0-12 h (modest but not statistically significant, 24.4 4 ± 7.40 versus 26.1 6 ± 7.32 mg·h·L(- 1)) were observed for grapefruit juice compared to fasted subjects. 4. Co-administration of pirfenidone with grapefruit juice resulted in modestly reduced overall oral absorption and significantly reduced peak concentrations compared to fasting, which was similar to effect of food ingestion. No adverse events were observed in the study, but relatively dramatic reduction of peak concentrations should raise concerns for clinical efficacy and safety.

Scientific ReportsQ3 · CROSS-FIELD

Network pharmacology based virtual screening of active constituents of Prunella vulgaris L. and the molecular mechanism against breast cancer

Q3 · CROSS-FIELD

ArticleOA

Author: Wang, Long ; Hu, Yuanzhang ; Shen, Tao ; Lin, Jingjing ; Gao, Rui ; Zhou, Xin ; Zhou, Zubin ; Tang, Xuehua ; Xu, Lu ; Zhang, Xiaobo

AbstractPrunella vulgaris L, a perennial herb widely used in Asia in the treatment of various diseases including cancer. In vitro studies have demonstrated the therapeutic effect of Prunella vulgaris L. against breast cancer through multiple pathways. However, the nature of the biological mechanisms remains unclear. In this study, a Network pharmacology based approach was used to explore active constituents and potential molecular mechanisms of Prunella vulgaris L. for the treatment of breast cancer. The methods adopted included active constituents prescreening, target prediction, GO and KEGG pathway enrichment analysis. Molecular docking experiments were used to further validate network pharmacology results. The predicted results showed that there were 19 active ingredients in Prunella vulgaris L. and 31 potential gene targets including AKT1, EGFR, MYC, and VEGFA. Further, analysis of the potential biological mechanisms of Prunella vulgaris L. against breast cancer was performed by investigating the relationship between the active constituents, target genes and pathways. Network analysis showed that Prunella vulgaris L. exerted a promising preventive effect on breast cancer by acting on tumor-associated signaling pathways. This provides a basis to understand the mechanism of the anti-breast cancer activity of Prunella vulgaris L.

100 Deals associated with Zhuhai Ebang Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Zhuhai Ebang Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Voriconazole ( CYP51A1 )	Invasive aspergillosis More	Phase 1
Bismuthyl Ecabet ( Protease )	Peptic Ulcer More	Pending
Apapenem ( PBPs )	Bacterial Infections More	Pending